Ibrutinib
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Ibrutinib
Ibrutinib: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Ibrutinib, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 11 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| leukemia, lymphocytic, chronic, b-cell | licence in another country |
| mantle-cell lymphoma | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| acute lymphoblastic/lymphocytic leukemia |
| b-cell neoplasm |
| graft versus host disease |
| lymphoplasmacytic lymphoma |
| lymphosarcoma |
| macroglobulinemia |
| mantle cell lymphoma |
| richter syndrome |
| waldenstrom macroglobulinemia |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 11213E | Imbruvica | Capsule 140 mg | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (BTK inhibitor), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the PI warnings and precautions |
| Monitoring Items | Full blood count; also consider cardiovascular status and bleeding, as noted in the PI |
| Handling Protection | Please refer to the PI and local institutional policy |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 potential interactions; the 20 listed in the data compiled for this report include:
- Major: aprepitant, acetylsalicylic acid (aspirin), clarithromycin, cobicistat and deferasirox.
- Moderate: examples include loperamide, dexamethasone, cimetidine, miconazole and the gliptins (saxagliptin, linagliptin, sitagliptin).
- Minor: prucalopride.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.